Literature DB >> 14515248

Mini-review: Regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming?

Cornelis J M Melief1.   

Abstract

Cross-priming is the process whereby professional APC, mainly dendritic cells (DC), prime T cells by presenting antigens processed from proteins of other cells such as tumor cells or virus-infected cells. It has been argued that the importance of cross-priming of CD8(+) CTL responses has been overemphasized, despite strong evidence that these mechanisms operate when infectious organisms, tumors or self antigens cannot efficiently access the biosynthetic MHC class I processing pathway of DC. Since DC are ideally equipped to capture exogenous antigen and also, particularly in the mature state, express costimulatory molecules, it is difficult to distinguish whether effects are due to cross-presentation, costimulation, or both. Whether cross-priming or cross-tolerance occurs depends on the maturation state of the DC, as well as the levels of MHC class I-bound peptides they present. Cross-presentation of tumor-derived antigens has been demonstrated but, importantly, requires adequate APC activation to prime CTL responses. Similarly, cross-presentation of antigens from infectious organisms appears to be common, and frequently leads to cross-priming. Interactions between cross-presenting DC, CD4(+) cells and CD8(+) T cells in the establishment of immunological memory are still not well defined. Experiments utilizing DC depletion are needed to further examine the role of processes such as cross-priming and costimulation in the immune response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14515248     DOI: 10.1002/eji.200324341

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  47 in total

1.  The pathway of cross-presentation is influenced by the particle size of phagocytosed antigen.

Authors:  Alexandra Mant; Fay Chinnery; Tim Elliott; Anthony P Williams
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

Review 2.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

Review 3.  Overview of the immune response.

Authors:  David D Chaplin
Journal:  J Allergy Clin Immunol       Date:  2010-02       Impact factor: 10.793

4.  MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells.

Authors:  Margaret Chen; Christina Barnfield; Tanja I Näslund; Marina N Fleeton; Peter Liljeström
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  A marked reduction in priming of cytotoxic CD8+ T cells mediated by stress-induced glucocorticoids involves multiple deficiencies in cross-presentation by dendritic cells.

Authors:  John T Hunzeker; Michael D Elftman; Jennifer C Mellinger; Michael F Princiotta; Robert H Bonneau; Mary E Truckenmiller; Christopher C Norbury
Journal:  J Immunol       Date:  2010-11-22       Impact factor: 5.422

6.  Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity.

Authors:  Nadine van Montfoort; Marcel G Camps; Selina Khan; Dmitri V Filippov; Jimmy J Weterings; Janice M Griffith; Hans J Geuze; Thorbald van Hall; J Sjef Verbeek; Cornelis J Melief; Ferry Ossendorp
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-03       Impact factor: 11.205

7.  An Efficient and High Yield Method for Isolation of Mouse Dendritic Cell Subsets.

Authors:  Pooja Arora; Steven A Porcelli
Journal:  J Vis Exp       Date:  2016-04-18       Impact factor: 1.355

8.  Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

Authors:  David H Munn; Madhav D Sharma; Deyan Hou; Babak Baban; Jeffrey R Lee; Scott J Antonia; Jane L Messina; Phillip Chandler; Pandelakis A Koni; Andrew L Mellor
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

9.  Direct presentation is sufficient for an efficient anti-viral CD8+ T cell response.

Authors:  Ren-Huan Xu; Sanda Remakus; Xueying Ma; Felicia Roscoe; Luis J Sigal
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

10.  Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells.

Authors:  Keiichi Moriya; Ayako Wakabayashi; Masumi Shimizu; Hideto Tamura; Kazuo Dan; Hidemi Takahashi
Journal:  Cancer Immunol Immunother       Date:  2010-03-10       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.